Skip to Content

Join the 'Chronic Myelogenous Leukemia (CML)' group to help and get support from people like you.

Chronic Myelogenous Leukemia (CML) News

Related terms: Cancer, Chronic Myelogenous Leukemia, Chronic Granulocytic Leukemia, Leukemia, Chronic Granulocytic, CML

Generic Gleevec Will Likely Cut Millions in Health Costs

Posted 19 Mar 2016 by Drugs.com

FRIDAY, March 18, 2016 – Using the generic form of the cancer drug Gleevec could save patients and insurers millions of dollars, a new study suggests. The patent on Gleevec expired in January. The generic version of the drug is called imatinib. The drug is used to treat chronic myeloid leukemia. Most people with chronic myeloid leukemia require lifelong daily medication, researchers said. "If we start all patients on the generic form of Gleevec and it works, then they are on a generic for the rest of their lives," study leader William Padula, an assistant professor at the Johns Hopkins Bloomberg School of Public Health in Baltimore, said in a school news release. "This amounts to a huge cost savings for them and their insurers." The researchers calculated that if all chronic myeloid leukemia patients began receiving imatinib immediately after diagnosis, the cost of treatment per ... Read more

Related support groups: Chronic Myelogenous Leukemia (CML), Gleevec, Imatinib

New Immune Therapy Achieves Complete Remission in Blood Cancer Patients

Posted 16 Feb 2016 by Drugs.com

A new therapy that uses a person's immune system to attack tumors led to complete remission in terminally ill blood cancer patients, according to researchers. In a clinical trial, symptoms vanished in 94 percent of leukemia patients who received the treatment. The response rate was more than 80 percent in patients with other blood cancers, and half achieved total remission, CNBC reported. The results were presented Monday at the annual meeting of the American Association for the Advancement of Science. Detailed data will be published later this year. They therapy involves removing immune system T-cells from patients, loading them with anti-cancer molecules, and placing them back in the body. The altered T-cells then seek and destroy cancer, CNBC reported. The results are unprecedented, according to researcher Stanley Riddell. "In the laboratory and in clinical trials, we are seeing ... Read more

Related support groups: Blood Disorders, Cancer, Hairy Cell Leukemia, Leukemia, Chronic Myelogenous Leukemia (CML), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Diagnosis and Investigation, Acute Lymphocytic Leukemia, Chronic Eosinophilic Leukemia, Acute Nonlymphocytic Leukemia, Acute Promyelocytic Leukemia, Infection Prophylaxis, Chronic Lymphocytic Leukemia, Meningeal Leukemia, Acute Myeloblastic Leukemia

Antibody May Lower Rejection Rates After Stem Cell Transplant in Leukemia Patients

Posted 7 Jan 2016 by Drugs.com

WEDNESDAY, Jan. 6, 2016 – People with acute leukemia who were given antibody therapy before a stem cell transplant fared better than those who didn't receive the treatment, a small study found. Stem cell transplantation allows doctors to give higher doses of cancer-killing chemotherapy, according to the American Cancer Society. However, the odds of the body rejecting the transplanted stem cells are very high – a condition called graft-versus-host disease, the study authors explained. By treating patients first with animal-derived antibodies, called antihuman T-lymphocyte immune globulin (ATG), the researchers were able to lower the threat of rejection in patients. "Graft-versus-host disease is the most serious complication after stem cell transplantation," said lead researcher Dr. Francesca Bonifazi, from the Institute of Hematology at Bologna University in Italy. "Using [ATG] reduces ... Read more

Related support groups: Hairy Cell Leukemia, Leukemia, Chronic Myelogenous Leukemia (CML), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Acute Lymphocytic Leukemia, Acute Nonlymphocytic Leukemia, Chronic Eosinophilic Leukemia, Infection Prophylaxis, Chronic Lymphocytic Leukemia, Acute Promyelocytic Leukemia, Acute Myeloblastic Leukemia, Meningeal Leukemia

End-of-Life Talk Often Comes Too Late for Blood Cancer Patients

Posted 21 Dec 2015 by Drugs.com

MONDAY, Dec. 21, 2015 – Many doctors wait too long to have end-of-life discussions with blood cancer patients, a new study finds. Researchers analyzed surveys completed by 349 blood cancer specialists, and found that 56 percent said end-of-life discussions with patients happen too late. Nearly 43 percent said they had their first end-of-life discussions with patients at less-than-ideal times, the findings showed. About 23 percent of the doctors said they waited until death was imminent before discussing hospice care. And nearly 40 percent waited until death was imminent before they asked patients where they wanted to die. Several factors may contribute to the delay in end-of-life discussions with blood cancer patients, according to Dr. Oreofe Odejide, from the Dana-Farber Cancer Institute in Boston, and colleagues. While solid tumors are incurable after they reach an advanced stage, ... Read more

Related support groups: Cancer, Hairy Cell Leukemia, Leukemia, Chronic Myelogenous Leukemia (CML), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Acute Lymphocytic Leukemia, Chronic Eosinophilic Leukemia, Acute Nonlymphocytic Leukemia, Acute Promyelocytic Leukemia, Infection Prophylaxis, Chronic Lymphocytic Leukemia, Meningeal Leukemia, Acute Myeloblastic Leukemia

Sun Pharma Announces FDA Approval for Generic Gleevec

Posted 6 Dec 2015 by Drugs.com

Mumbai, December 04, 2015: Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, Sun Pharma) today announced that one of its subsidiaries has received final approval from US FDA for its Abbreviated New Drug Application (ANDA) for generic version of Gleevec, Imatinib Mesylate tablets 100mg and 400mg. Imatinib Mesylate tablets, 100 mg and 400 mg are therapeutic equivalents of Novartis’ Gleevec tablets. As per IMS MAT August 2015, these tablets have annual sales of approximately US$ 2.5 billion in the US. These tablets are indicated for the treatment of chronic myeloid leukemia. The Sun Pharma subsidiary, being the first-to-file an ANDA for generic Gleevec with a para IV certification, is eligible for 180-days marketing exclusivity in the US. Under the terms of a settlement agreement with Novartis, the Sun Pharma subsidiary is permitted to l ... Read more

Related support groups: Chronic Myelogenous Leukemia (CML), Gleevec, Imatinib

Young Cancer Survivors Often Develop New Malignancies

Posted 6 Oct 2015 by Drugs.com

TUESDAY, Oct. 6, 2015 – Teen and young adult cancer survivors are at increased risk for other cancers later in life, a new study reveals. Researchers analyzed U.S. National Cancer Institute data on people who survived cancers before age 40. They had the most common types of cancers in that age group: leukemia, lymphoma, testicular, ovarian, thyroid, breast, soft tissue and bone cancers. "This is a patient demographic that has been largely overlooked," said senior study author Dr. Robert Goldsby, a professor of pediatrics at the University of California, San Francisco Benioff Children's Hospital. Over 30 years, nearly 14 percent of the survivors were diagnosed with another, different type of cancer. On average, the second cancer occurred within 15 years. Compared to people in the general population, patients successfully treated for cancer between ages 15 and 39 were nearly 60 percent ... Read more

Related support groups: Cancer, Breast Cancer, Hairy Cell Leukemia, Leukemia, Chronic Myelogenous Leukemia (CML), Lymphoma, Basal Cell Carcinoma, Melanoma, Skin Cancer, Chronic Lymphocytic Leukemia (CLL), Ovarian Cancer, Non-Hodgkin's Lymphoma, Acute Myeloid Leukemia, Stomach Cancer, Cutaneous T-cell Lymphoma, Hodgkin's Lymphoma, Acute Lymphoblastic Leukemia, Soft Tissue Sarcoma, Acute Lymphocytic Leukemia, Testicular Cancer

Could Common Diabetes Drugs Help Fight Leukemia?

Posted 2 Sep 2015 by Drugs.com

WEDNESDAY, Sept. 2, 2015 – Common diabetes drugs might help eradicate drug-resistant cancer cells in a certain form of leukemia when added to standard treatment, a small new study suggests. Researchers found that patients with chronic myeloid leukemia (CML) who received a glitazone – a class of drug for type 2 diabetes – along with the standard CML drug imatinib remained disease-free for up to nearly five years. Imatinib, known commercially as Gleevec, boasts an impressive track record in controlling chronic myeloid leukemia and allowing patients to lead virtually normal lives. But despite its effectiveness, dormant, drug-resistant leukemic cells typically lay in wait in bone marrow. They can later transform into highly aggressive cells. "Gleevec can control the disease but never get rid of the source of the disease," said Lee Greenberger, chief scientific officer for the Leukemia & ... Read more

Related support groups: Chronic Myelogenous Leukemia (CML), Gleevec, Actos, Pioglitazone, Avandia, ActoPlus Met, Imatinib, Avandamet, Rosiglitazone, Metformin/Pioglitazone, Oseni, Alogliptin/pioglitazone, Glimepiride/Pioglitazone, ActosPlus Met, Glimepiride/Rosiglitazone, Avandaryl, Metformin/Rosiglitazone, Duetact

FDA Approves U.S. Product Labeling Update for Sprycel (dasatinib) to Include Three-Year First-Line and Five-Year Second-Line Efficacy and Safety Data in Chronic Myeloid Leukemia in Chronic Phase

Posted 23 Jun 2013 by Drugs.com

Data added to Sprycel U.S. labeling are among the longest follow-up data of current CML treatment options PRINCETON, N.J., June 20, 2013--(BUSINESS WIRE)--Bristol-Myers Squibb Company and Otsuka America Pharmaceutical, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved an update to the Sprycel (dasatinib) product labeling. The labeling now includes three-year efficacy and safety data in patients with newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase (CP) and five-year data in CP Ph+ CML patients who are resistant or intolerant to Gleevec1 (imatinib mesylate). Sprycel is a kinase inhibitor indicated for the treatment of adults with newly diagnosed CP Ph+ CML. The effectiveness of Sprycel is based on cytogenetic response and major molecular response rates. The trial is ongoing and further data will be ... Read more

Related support groups: Chronic Myelogenous Leukemia (CML), Sprycel, Dasatinib

Gene Discovery May Offer Breakthrough for Rare Leukemia

Posted 10 May 2013 by Drugs.com

THURSDAY, May 9 – In the war against cancer, it looks like matchmaking – between genes and drugs – could be an important tool, according to new research into the genetic underpinnings of two rare forms of leukemia. By matching a patient's genetic mutation responsible for a rare, rapidly progressing form of leukemia with a drug that specifically targets the problem the mutation creates, researchers report that one patient is experiencing fast, marked improvement. The new findings shed light on how many forms of cancer may be tackled in the near future. Scientists are discovering how to differentiate between mutations that are driving the proliferation of cancer cells and those that are merely passengers in the process. "If your car breaks down, you have to open up the hood to see what part has broken," said study author Jeffrey Tyner, an assistant professor at the Knight Cancer ... Read more

Related support groups: Leukemia, Chronic Myelogenous Leukemia (CML)

Soaring Prices Keep Leukemia Drugs From Patients, Experts Say

Posted 25 Apr 2013 by Drugs.com

THURSDAY, April 25 – Pricey cancer medications prevent many Americans with chronic myeloid leukemia (CML) from receiving lifesaving treatment, an international team of experts claims. These drugs can cost more than $100,000 a year for patients with CML, once considered a death sentence but now highly treatable with ongoing treatment, according to a commentary penned by 120 specialists in more than 15 countries and published online April 25 in the journal Blood. "Patients with CML have a much better outlook today than ever before, thanks to advances that have greatly improved survival rates. But these patients now face dire financial struggles as they try to maintain their treatment regimen with the drastically inflating cost of care," corresponding author Dr. Hagop Kantarjian, chairman of the leukemia department at the University of Texas MD Anderson Cancer Center in Houston, said in a ... Read more

Related support groups: Leukemia, Chronic Myelogenous Leukemia (CML), Gleevec, Sprycel, Imatinib, Dasatinib, Bosulif, Bosutinib, Omacetaxine, Synribo

FDA Approves Iclusig to Treat Two Rare Types of Leukemia

Posted 17 Dec 2012 by Drugs.com

December 14, 2012 - The U.S. Food and Drug Administration today approved Iclusig (ponatinib) to treat adults with chronic myeloid leukemia (CML) and Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL), two rare blood and bone marrow diseases. Iclusig is being approved more than three months ahead of the product’s prescription user fee goal date of March 27, 2013, the date the agency was scheduled to complete review of the drug application. The FDA reviewed the Iclusig drug application under the agency’s priority review program, which provides for an expedited six-month review for drugs that may provide safe and effective therapy when no satisfactory alternative therapy exists, or offer significant improvement compared to marketed products. Iclusig blocks certain proteins that promote the development of cancerous cells. The drug is taken once a day to treat patients ... Read more

Related support groups: Leukemia, Chronic Myelogenous Leukemia (CML), Acute Lymphoblastic Leukemia

FDA Approves Synribo for Chronic Myelogenous Leukemia

Posted 28 Oct 2012 by Drugs.com

October 26, 2012 - The U.S. Food and Drug Administration today approved Synribo (omacetaxine mepesuccinate) to treat adults with chronic myelogenous leukemia (CML), a blood and bone marrow disease. An estimated 5,430 people will be diagnosed with CML in 2012, according to the National Institutes of Health. Synribo is intended to be used in patients whose cancer progressed after treatment with at least two drugs from a class called tyrosine kinase inhibitors (TKIs), also used to treat CML. Synribo blocks certain proteins that promote the development of cancerous cells. It is injected just under the skin (subcutaneously) twice daily for 14 consecutive days over a 28-day cycle until white blood cell counts normalize (hematologic response). Synribo is then administered twice daily for seven consecutive days over a 28-day cycle as long as patients continue to clinically benefit from ... Read more

Related support groups: Chronic Myelogenous Leukemia (CML)

Bosulif Approved for Rare Leukemia

Posted 5 Sep 2012 by Drugs.com

WEDNESDAY, Sept. 5 – Bosulif (bosutinib) has been approved by the U.S. Food and Drug Administration to treat chronic myelogenous leukemia (CML), a cancer of the blood and bone marrow that primarily affects older people, the agency said in a news release. Some 5,430 people are expected to be diagnosed this year with the disease, which primarily is caused by a genetic mutation called the Philadelphia chromosome, the FDA said. This abnormality causes a person's bone marrow to produce an enzyme that triggers development of abnormal white blood cells known as granulocytes. The new drug works to block the effects of this enzyme. Bosulif was evaluated in a clinical trial that included 546 adults with CML. The drug's most common side effects included diarrhea, nausea, low blood platelets, abdominal pain, rash, anemia, fever and fatigue. The drug is marketed by Pfizer, based in New York City. ... Read more

Related support groups: Chronic Myelogenous Leukemia (CML)

FDA Approves Bosulif for Chronic Myelogenous Leukemia

Posted 4 Sep 2012 by Drugs.com

September 4, 2012 – The U.S. Food and Drug Administration today approved Bosulif (bosutinib) to treat chronic myelogenous leukemia (CML), a blood and bone marrow disease that usually affects older adults. An estimated 5,430 men and women will be diagnosed with CML in 2012. Most people with CML have a genetic mutation, called the Philadelphia chromosome, which causes the bone marrow to make an enzyme called tyrosine kinase. This enzyme triggers the development of too many abnormal and unhealthy white blood cells called granulocytes. Granulocytes fight infection. Bosulif is intended for patients with chronic, accelerated or blast phase Philadelphia chromosome positive CML who are resistant to or who cannot tolerate other therapies, including imatinib. Bosulif works by blocking the signal of the tyrosine kinase that promotes the development of abnormal and unhealthy granulocytes. “With ... Read more

Related support groups: Leukemia, Chronic Myelogenous Leukemia (CML)

Leukemia Patients Taking Gleevec Achieve 'Normal' Death Rate

Posted 22 Mar 2011 by Drugs.com

TUESDAY, March 22 – The death rate of patients with chronic myeloid leukemia who took Gleevec and were in remission two years after treatment was similar to the death rate in the general population, a new study shows. Italian researchers collected data on 832 patients who were taking Gleevec (imatinib) for up to eight years and found that 20 patients died during the follow-up period. That death rate of 4.8 percent, however, is similar to what would be expected in the general population. Only six deaths were related to chronic myeloid leukemia (CML), the researchers noted. Serious adverse events such as cardiovascular and digestive problems were reported in 139 patents, but only 27 cases (19 percent) were considered to be related to Gleevec, according to the study. Other adverse events frequently connected to Gleevec included muscle cramps, weakness, edema, skin fragility, diarrhea, and ... Read more

Related support groups: Chronic Myelogenous Leukemia (CML), Gleevec

Page 1 2 Next

Ask a Question

Further Information

Related Condition Support Groups

Leukemia

Related Drug Support Groups

Gleevec, Tasigna, Sprycel, hydroxyurea, Hydrea, Cytoxan, cyclophosphamide, PegIntron, anagrelide, view more... imatinib, dasatinib, nilotinib, interferon alfa-2a, Droxia, bosutinib, peginterferon alfa-2b, Bosulif, cytarabine, Agrylin, Cytosar, ponatinib, Iclusig, Roferon-A, Cytosar-U, fludarabine, Fludara, busulfan, Synribo, omacetaxine, Mylocel, Cytoxan Lyophilized, Neosar, Tarabine PFS, Myleran, Busulfex